A review of tasquinimod in the treatment of advanced prostate cancer
Williamson SC, Hartley AE, Heer R. Drug Des Devel Ther. 2013 Mar 21;7:167-74. doi: 10.2147/DDDT.S31500. Print 2013.

Source

Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK.

Abstract

Castration resistant prostate cancer remains a major clinical burden and novel therapeutic options are urgently required to improve survival. Tasquinimod is an orally administered quinoline-3-carboxamide with potent antiangiogenic and antitumorigenic action that has shown promise in the treatment of advanced prostate cancers. This review explores both preclinical and clinical findings to date. In summary, tasquinimod has been shown to demonstrate a potent in vitro and in vivo anticancer action and completed early phase clinical trials have demonstrated good drug tolerance and prolonged progression-free survival. Although Phase III clinical trials are on-going, the findings to date highlight the promise of this drug in the treatment of advanced prostate cancer.